Bacterial Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer.
Pathogen-pathogen interactions during co-infections.
Microbial extracellular vesicles contribute to antimicrobial resistance.
Understanding bacterial biofilms: From definition to treatment strategies.
Metals to combat antimicrobial resistance.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
- Q1 2027A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
Clinical MilestonesViewHide
- 2026-07-01A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTIONResults expected Q1 2027
- 2026-06-04An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial InfectionsResults expected Q4 2026
- 2026-07-30A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants With Renal ImpairmentPrimary completion
- 2026-07-01[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human SubjectsPrimary completion
- 2026-04-30A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of CarePrimary completion
- 2025-12-31A Randomized, Double-blind, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of the Drug Fluorothiazinone (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on Mechanical VentilationPrimary completion
- 2026-07-30ClinicalA Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants With Renal ImpairmentPrimary completion
- 2026-07-01ClinicalA PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTIONResults expected Q1 2027
- 2026-07-01Clinical[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human SubjectsPrimary completion
- 2026-06-04ClinicalAn Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial InfectionsResults expected Q4 2026
- 2026-04-30ClinicalA Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of CarePrimary completion
- 2026-02-24ClinicalIntegrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus InfectionResults posted
- 2025-12-31ClinicalA Randomized, Double-blind, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of the Drug Fluorothiazinone (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on Mechanical VentilationPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)
Approval — Xydalba is indicated for the treatment of acute bacterial skin and skin structure infecti… (2015)
Approval — Sivextro tablets are indicated for the treatment of acute bacterial skin and skin structu… (2015)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Bacterial Infections10
- Drug Resistance, Bacterial5
- Bacteria3
- Global Health3
- Anti-Infective Agents2
- Extracellular Vesicles2
- Host-Pathogen Interactions2
- Microbiota2
Leading journals6
- Emerging infectious diseases3
- International journal of molecular sciences3
- Lancet (London, England)3
- FEMS microbiology reviews2
- Frontiers in public health2
- The Lancet. Infectious diseases2
Leading researchers8
- Liu Y2
- Abbas K1
- Adler Y1
- Alloisio G1
- Alvarez-Uria G1
- Amin-Chowdhury Z1
- Antunes LCM1
- Ascenzi P1
Affiliations (unnormalised)6
- Centre for Tropical Medicine and Global Health2
- Department of Laboratory Medicine2
- Oxford University Clinical Research Unit2
- Akershus University Hospital1
- Amsterdam University Medical Center1
- Angkor Hospital for Children1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Bacterial infections are infections caused by bacteria, or infections in which bacteria are the unspecified causative agents. The literature grounding emphasizes their relevance across microbiology, transmission, mortality, prevention and control, and treatment. It also highlights that bacterial infections can involve host-pathogen interactions, adhesion, quorum sensing, microbiota, symbiosis, and biofilm formation.
The grounding supports bacterial infection as being caused by bacteria in general, without specifying a single organism or syndrome. It also indicates that transmission and persistence on inanimate surfaces can contribute to spread in nosocomial settings. Antimicrobial resistance is not a cause of infection itself, but it is a major feature of bacterial pathogens that complicates treatment and burden.
Bacterial infections involve interactions between bacteria and the host, including adhesion to surfaces or tissues, quorum sensing, and biofilm formation. Biofilms create structured microbial communities with an extracellular matrix, altered gene expression, and reduced growth rates, which can support persistence and genetic exchange. Host immune responses, including IL-10-mediated suppression of Th1 cells, NK cells, and macrophages, can also influence pathogen clearance and tissue damage during infection.
The grounding supports exposure to contaminated inanimate surfaces and nosocomial environments as risk factors for acquisition and persistence of bacterial pathogens. Biofilm-associated settings and device-related infections are also highlighted as important contexts for infection. Antimicrobial resistance increases the burden and complicates management, but the supplied material does not support broader patient-level risk factors.
Treatment is described at the level of drug therapy and therapy, with antibiotics as the central modality for bacterial infections. The grounding also supports prevention and control measures, including approaches aimed at transmission reduction and infection control in healthcare settings. Because antimicrobial resistance is a major issue, the literature also points to antimicrobial stewardship and development of new antibacterial agents or anti-virulence strategies such as quorum-sensing inhibition.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Infections by bacteria, general or unspecified.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.